Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's performance for the week of May 26 to May 30 was a 2.21% increase, ranking second among 31 industries, and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has increased by 6.61%, ranking sixth and outperforming the CSI 300 by 9.02 percentage points. The top three sub-sectors were chemical pharmaceuticals (3.83%), biological products (3.14%), and medical services (2.46%) [4][13][15]. Industry News - On May 29, the National Medical Products Administration (NMPA) approved 11 innovative drugs, with 9 being domestically developed, showcasing the increasing innovation capability of China's pharmaceutical industry. Additionally, during the 2025 American Society of Clinical Oncology (ASCO) annual meeting, significant clinical data was presented for various treatments, indicating the growing recognition of domestic innovative drug companies [5][29][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector, which is seen as the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. It also recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services. Specific stock recommendations include Beida Pharmaceutical, Teva Biopharma, Qianhong Pharmaceutical, Lingrui Pharmaceutical, and Lao Baixing, with additional stocks to watch including Kelun Pharmaceutical, Rongchang Biopharma, Kaili Medical, Huaxia Eye Hospital, and Baipusais [6][35].

业 及 产 业 医药生物 行 业 研 究 / 行 业 点 相关研究 《本周医药上涨 1.8%，三生/辉瑞达成超 60 亿美元 BD 合作，ASCO 摘要公布国产 创新药表现亮眼 ——医药行业周报 （2025/5/19-2025/5/23）》 2025/05/25 《本周医药上涨 1.3%，恒瑞正式启动港股 招股，健友/双成合作白紫品种美国 ANDA 获批 ——医药行业周报（2025/5/12- 2025/5/16）》 2025/05/18 证券分析师 张静含 A0230522080004 zhangjh@swsresearch.com 研究支持 李敏杰 A0230523070006 limj2@swsresearch.com 联系人 李敏杰 (8621)23297818× limj2@swsresearch.com 2025 年 06 月 02 日 本周医药上涨 2.2%，石药近期或 完成 3 笔超 50 亿美元授权交易， 11 款创新药同日获批 看好 ——医药行业周报（2025/5/26-2025/5/30） 本期投资提示： 证 券 研 究 报 告 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通 ...

Group 1 - The A-share market experienced a pullback on the last trading day before the Dragon Boat Festival, with 1,116 stocks rising and 4,163 stocks falling [1] - The innovative drug sector performed well, with several pharmaceutical stocks leading in gains, while the drone industry chain stock Haige Communication hit the daily limit [1] - High dividend assets such as banks and highways showed strength in the market [1] Group 2 - The 61st session of the stock picking competition concluded with the champion achieving a return of 43.94%, the runner-up at 40.33%, and the third place at 38.21% [1] - A total of 639 participants achieved positive returns in this session, all of whom will receive cash rewards [1] Group 3 - The 62nd session of the competition will start registration on May 31, with simulated trading funds of 500,000 yuan [2][13] - Weekly cash rewards will be distributed based on performance, with the first place receiving 688 yuan and other top positions also receiving cash prizes [2][13] Group 4 - The top performers in the competition capitalized on sectors such as controllable nuclear fusion and blockchain, with significant returns noted [3][8] - The monthly points leader "X5" achieved returns of 17.32%, 26.41%, and 28.45% in the three sessions of May [6] Group 5 - The competition's structure allows for more frequent rewards, with participants encouraged to trade at least three stocks to maximize their points [14] - Participants can gain access to exclusive market insights and analysis through the "Fire Line Quick Review" service upon registration [10][15] Group 6 - The innovative drug sector is highlighted as a promising investment opportunity, with several new drugs approved for market release [11] - The drone industry is also gaining attention, with the first flight of a domestically developed drone expected by the end of June [11]

Market Overview - The last trading day before the Dragon Boat Festival saw a volume contraction in the two markets, with the pharmaceutical sector experiencing a broad rally, particularly in Alzheimer's, innovative drugs, and CROs [1] - Several stocks, including Ruizi Pharmaceutical, Wanbangde, and Hainan Haiyao, hit the daily limit up [1] - The pork and chicken sectors also saw a rise, while bank stocks remained active, with Hangzhou Bank and Chengdu Bank reaching new historical highs [1] Banking Sector - Despite the strong performance of bank stocks, a sell-off occurred in multiple bank stocks towards the end of the trading session, indicating a potential profit-taking behavior ahead of the holiday [8] - Regional banks like Hangzhou Bank and Chengdu Bank attracted end-of-day funds due to their earnings elasticity, but this was not enough to offset the selling pressure from larger state-owned banks [8] - The banking sector has been a focus for investors this year, driven by increasing risk aversion, and is expected to remain a key market theme post-holiday [8] Pharmaceutical Sector - On May 29, the National Medical Products Administration approved 11 innovative drugs for market entry, a notably rare occurrence [10] - Among these, five were from innovative companies listed on the Sci-Tech Innovation Board, indicating a supportive policy environment for the innovative drug sector [10] - The current valuation of the innovative drug industry stands at a price-to-earnings ratio (TTM) of 27.74, with a 150% premium over the CSI 300 index, suggesting a stable growth outlook despite recent net outflows from the sector [10] Social Security Fund Holdings - A summary of the latest holdings by the Social Security Fund highlights several pharmaceutical stocks, including Wo Wu Biological, Jiuzhou Pharmaceutical, and others, with varying market capitalizations and price-to-earnings ratios [12] - The data indicates a focus on companies with strong growth potential and established market positions within the pharmaceutical sector [12]

Group 1 - The China Securities 500 Quality Growth Index (930939) decreased by 0.57% as of May 30, 2025, with mixed performance among constituent stocks [1] - Debon Securities (603056) led the gains with an increase of 9.99%, while Te Bao Biological (688278) experienced the largest decline at 4.49% [1] - The 500 Quality Growth ETF (560500) fell by 0.63%, with the latest price at 0.94 yuan and a trading volume of 3.383 million yuan [1] Group 2 - From January to April 2025, the profits of industrial enterprises above designated size increased by 1.4% year-on-year, driven by a narrowing decline in profit margins [1] - The improvement in profit growth is expected to continue in May, supported by the easing of China-US trade relations and the "export rush effect" due to tariff exemptions [1] - The top ten weighted stocks in the China Securities 500 Quality Growth Index as of April 30, 2025, accounted for 24.07% of the index, with Chifeng Gold (600988) being the largest component [2]

Group 1 - The core viewpoint of the news highlights the positive market reaction to the approval of 11 innovative drugs by the National Medical Products Administration, leading to a rise in the related stocks of innovative pharmaceutical companies [1] - The Science and Technology Conference on June 24 emphasized the focus on biotechnology and technological innovation, providing long-term support for the biopharmaceutical industry [2] - The research from securities firms indicates that the internationalization of Chinese innovative drugs is progressing, with significant representation at the 2025 ASCO conference and record upfront payments for licensing agreements, showcasing the global competitiveness of companies like Zai Lab [2] Group 2 - The performance of the ChiNext Biopharmaceutical ETF (588250.SH) and its constituent stocks, such as EdiGene and Zai Lab, reflects a strong market sentiment towards innovative drug approvals [1] - The major constituent stocks of the ETF, including EdiGene, Zai Lab, and others, have shown significant price increases, indicating investor confidence in the sector [1] - The list of associated products and stocks includes various innovative pharmaceutical companies, highlighting the breadth of the sector's representation [3]

Group 1: Regulatory Oversight - The National Healthcare Security Administration (NHSA) is investigating potential violations related to pharmacists' credentials in retail pharmacies, with findings indicating that some pharmacists' names appear in multiple pharmacies, suggesting possible credential fraud or "hanging certificates" [1] - The investigation involves 24 provinces, 23,997 retail pharmacies, and 9,563 pharmacists, highlighting the widespread nature of the issue [1] - The NHSA has mandated self-inspections by pharmacists and comprehensive checks by pharmacies to ensure compliance and proper role fulfillment [1] Group 2: Drug Approvals - Heng Rui Medicine's new drug, injection of Rui Kang Qu Mo Zhu San, has received approval for treating adults with HER2-positive non-small cell lung cancer who have undergone at least one prior systemic therapy [3] - Te Bao Bio's long-acting growth hormone injection has been approved for treating growth hormone deficiency in children aged three and above [4] - Fosun Pharma's new small molecule cancer drug, Lu Wo Mei Ti Ni, has been approved for treating Langerhans cell histiocytosis and symptomatic neurofibromatosis type I in children and adolescents [11] Group 3: Financing Activities - Field Medical has completed a $40 million Series A financing round, aimed at advancing research and commercialization of its PFA system for treating ventricular tachycardia and atrial fibrillation [6] - Ausper Biopharma has announced a $50 million B+ financing round to support the clinical development of its innovative antisense oligonucleotide drug AHB-137 for chronic hepatitis B [7] - Ji Min Health's subsidiary has signed a strategic cooperation framework agreement with Da Bo Bio to accelerate new drug development and clinical transformation [8]

Group 1 - The U.S. Court of Appeals has temporarily reinstated the tariff policy from the Trump administration, allowing the government to implement tariffs on multiple countries until further notice [2] - The court's decision comes after the U.S. International Trade Court had previously issued a ruling to prohibit the enforcement of these tariffs [2] Group 2 - Foreign investors are regaining confidence in Chinese assets, with some adjusting their positions to a higher allocation [3] - The recovery in confidence is attributed to the ongoing "value reassessment" of Chinese tech stocks and the expansion of service consumption [3] - Policies aimed at boosting consumption and domestic demand have drawn attention to the consumer sector [3] Group 3 - The Chinese Ministry of Foreign Affairs has condemned the U.S. decision to revoke student visas for Chinese students, claiming it harms their legitimate rights and disrupts cultural exchanges [4][5] - The ministry has expressed a desire for constructive actions to improve Sino-U.S. relations [5] Group 4 - The National Bureau of Statistics of China is working on guidelines for the "data factor ×" application scenarios to enhance economic and social development [6][7] - The initiative aims to leverage the multiplier effect of data elements [6] Group 5 - Domestic airlines in China will reduce fuel surcharges starting June 5, 2025, with specific adjustments based on flight distance [9] - This reduction is expected to stimulate consumer demand as the summer travel season approaches [9] Group 6 - Nezha Auto's debt-to-equity swap plan has failed, with only partial debt relief achieved, leading to significant operational changes including the removal of its logo from its headquarters [12][13] - The company is reportedly relocating to a smaller office due to reduced staff [13] Group 7 - The human-robot industry is seeing potential IPO activity, with Yushutech changing its name to indicate a possible transition to a public company [13] - This name change is viewed as a routine operational adjustment, although it raises speculation about future funding [13] Group 8 - The renewable energy sector is reaching a critical point with significant transformations in operations and trading [14] - The camping economy is gaining attention, with companies actively positioning themselves in this growing market [14] - The film industry has seen a total box office exceeding 1.5 billion yuan in May, with many films set for the summer release [14] Group 9 - A-share market indices showed positive performance, with the Shanghai Composite Index closing at 3363.45 points, up 0.70% [14] - The Hong Kong stock market also experienced gains, particularly in the technology sector, with the Hang Seng Tech Index rising by 2.46% [15] Group 10 - Analysts predict that the A-share market will face some pressure in June but expect a solid bottom, with a positive outlook for Chinese assets [16][17] - There is an anticipated shift in foreign capital allocation towards A-shares, driven by stable economic conditions and low market valuations [17]

Core Viewpoint - The approval of Yipeisheng (益佩生), a long-acting growth hormone injection by Tebao Biopharma, marks a significant shift in the long-acting growth hormone market, breaking the decade-long monopoly held by Jinsai Pharmaceutical [2][4]. Company Summary - Tebao Biopharma's Yipeisheng is designed for weekly administration, targeting growth hormone deficiency in children aged three and above, enhancing patient compliance and reducing treatment burden [2][3]. - The company reported a revenue of 2.817 billion yuan in 2024, a year-on-year increase of 34.13%, and a net profit of 828 million yuan, up 49% year-on-year [6]. - The company has five existing products, with Paigebin being the main revenue driver, generating 2.447 billion yuan, accounting for over 80% of total revenue [6]. Industry Summary - The long-acting growth hormone market has been dominated by Jinsai Pharmaceutical for over ten years, with its product "Jinsai Zeng" being the first globally approved long-acting growth hormone [3][4]. - The market for growth hormone treatment in China is significant, with approximately 6.4 million children affected by growth hormone deficiency, indicating a substantial unmet medical need [3]. - The entry of Yipeisheng is expected to intensify competition in the long-acting growth hormone sector, potentially leading to expanded indications and increased market share for long-acting products [4].